SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases
| Autor: | Anja Strangfeld, Ana M. Rodrigues, Loreto Carmona, Ludovic Trefond, Charalampos Papagoras, Laure Gossec, N Roux, Kimme L. Hyrich, Saskia Lawson-Tovey, Bernd Raffeiner, Elsa F Mateus, Gözde Kübra Yardımcı, Pedro Machado, Xavier Mariette |
|---|---|
| Přispěvatelé: | NIHR Manchester Biomedical Research Centre [Manchester] (BRC [Manchester]), Manchester Academic Health Science Centre (MAHSC), University of Manchester [Manchester], Centre for Genetics and Genomics Versus Arthritis, Centre for Epidemiology Versus Arthritis, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Deutsches Rheuma-ForschungsZentrum (DRFZ), Deutsches Rheuma-ForschungsZentrum, Instituto de Salud Musculoesqueletica (InMusc), Central Hospital of Bolzano, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Hôpital privé Robert-Schuman, Metz, France., Sociedade Portuguesa de Reumatologia [Lisboa], Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Democritus University of Thrace (DUTH), Liga Portuguesa Contra as Doenças Reumaticas (LPCDR), EULAR PARE [Zurich, Switzerland], Université Paris-Saclay, Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, University College of London [London] (UCL), NIHR Biomedical Research Centre [London], Guy's and St Thomas' NHS Foundation Trust-King‘s College London, University College London Hospitals (UCLH), London North West University Healthcare NHS Trust (LNWH), European Alliance of Associations for Rheumatology, Service de Rhumatologie [CHU Pitié Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Molé, Christine |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty COVID-19 Vaccines Immunology Population Comorbidity General Biochemistry Genetics and Molecular Biology Rheumatology Rheumatic Diseases Internal medicine Epidemiology medicine Humans Immunology and Allergy Registries Adverse effect education Aged Aged 80 and over [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system education.field_of_study business.industry Abatacept COVID-19 Middle Aged vaccination Vaccine efficacy Vaccination [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system Antirheumatic Agents Hypertension [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Female epidemiology Rituximab business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩ Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217 Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩ |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2021-221217 |
| Popis: | Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are often treated with immunomodulatory or immunosuppressive medications; consequently, they have been excluded alongside other immunocompromised patients from late stages of SARS-CoV-2 vaccine trials. SARS-CoV-2 vaccine efficacy in this population is unclear, though initial data are reassuring overall. However, a slightly lower SARS-CoV-2 immunogenicity of vaccines has been documented in some patients with iRMD.1 2 Some common rheumatic and musculoskeletal disease (RMD) medications have been highlighted as possible influential factors on immunogenicity, particularly rituximab (RTX), mycophenolate mofetil (MMF), methotrexate (MTX), abatacept and glucocorticoids.3–7 The European Alliance of Associations for Rheumatology (EULAR) launched a COVID-19 registry in March 2020, capturing COVID-19 outcomes in the European RMD population. Questions on reinfection and vaccination were added in January 2021. A further EULAR registry (COVAX) was launched in February 2021 to collect data on COVID-19 vaccination and related adverse events among patients with RMD. Here we describe a series of patients who contracted SARS-CoV-2 infection after COVID-19 vaccination between 19 January 2021 and 27 July 2021. The series consists of 38 adults with iRMDs, 8 from the COVID-19 registry ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|